Contact
searchSearch
HMP Global

Diffuse Large B-Cell Lymphoma Resource Center

Diffuse Large B-Cell Lymphoma
Learning Library

New & Trending

EZH2
Rapid Refresh
Understanding the Role of EZH2 in Cancer Pathogenesis
02/28/2024
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role...
02/28/2024
Oncology Learning Network APP Institute
Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023
Oluwatobi Odetola, MD
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
From Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023
Narendranath Epperla, MD, MS
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
From Oncology

Clinical Pearls

EZH2
Rapid Refresh
Understanding the Role of EZH2 in Cancer Pathogenesis
02/28/2024
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role...
02/28/2024
Oncology Learning Network APP Institute
Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023
Oluwatobi Odetola, MD
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023
Narendranath Epperla, MD, MS
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
Andrew Lin, PharmD
Conference Coverage
Exploring Clinical Approaches to Managing CAR-T and Bispecific Therapy Toxicities
02/17/2026
Andrew Lin, PharmD, reviewed practical strategies for managing cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and cytopenias associated with CAR T-cell and bispecific therapies.
Andrew Lin, PharmD, reviewed practical strategies for managing cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and cytopenias associated with CAR T-cell and bispecific therapies.
Andrew Lin, PharmD, reviewed...
02/17/2026
Oncology Learning Network APP Institute
Donna Catamero, ANP-BC, OCN, CCRC
Conference Coverage
Exploring the Rapidly Evolving Landscape of Targeted Therapy for Multiple Myeloma
02/11/2026
Donna Catamero, ANP-BC, OCN, CCRC
Donna Catamero, ANP-BC, OCN, CCRC, highlighted the rapidly evolving multiple myeloma treatment landscape, with quadruplet therapy now standard in newly diagnosed disease, earlier use of CAR-T therapy in relapse, and emerging bispecific and...
Donna Catamero, ANP-BC, OCN, CCRC, highlighted the rapidly evolving multiple myeloma treatment landscape, with quadruplet therapy now standard in newly diagnosed disease, earlier use of CAR-T therapy in relapse, and emerging bispecific and...
Donna Catamero, ANP-BC, OCN,...
02/11/2026
Oncology Learning Network APP Institute
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP
Conference Coverage
Clinical Strategies for the Assessment and Management of Antibody-Drug Conjugate Toxicities
01/30/2026
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP, reviewed the mechanisms, expanding clinical use, and payload-driven toxicities of antibody-drug conjugates, emphasizing practical strategies for toxicity recognition, management, and optimizing patient...
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP, reviewed the mechanisms, expanding clinical use, and payload-driven toxicities of antibody-drug conjugates, emphasizing practical strategies for toxicity recognition, management, and optimizing patient...
Sri Kota, MSN, BA, APN, AGNP-C,...
01/30/2026
Oncology Learning Network APP Institute
Jessica Walchonski, PA-C, MMS
Conference Coverage
Exploring Key Advances and Emerging Therapies in Gynecologic Oncology
01/23/2026
Jessica Walchonski, PA-C, MMS
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS,...
01/23/2026
Oncology Learning Network APP Institute
Allison Tanner, PA-C
Conference Coverage
Evolving Toxicity Management Strategies for CAR T-Cell and Bispecific Therapies
01/16/2026
Allison Tanner, PA-C
Allison Tanner, PA-C, reviewed the recognition and management of CRS, ICANS, and other evolving toxicities associated with CAR T-cell therapy and bispecific antibodies, emphasizing the need for clinician readiness as cellular therapies...
Allison Tanner, PA-C, reviewed the recognition and management of CRS, ICANS, and other evolving toxicities associated with CAR T-cell therapy and bispecific antibodies, emphasizing the need for clinician readiness as cellular therapies...
Allison Tanner, PA-C, reviewed...
01/16/2026
Oncology Learning Network APP Institute
Amy Goodrich, RN, BSN, MSN, CRNP-AC
Conference Coverage
Refining Treatment Pathways: Data-Driven Approaches to Sequencing in Lymphoma
01/08/2026
Amy Goodrich, RN, BSN, MSN, CPNP-AC
Amy Goodrich, RN, BSN, MSN, CRNP-AC, reviewed emerging treatments and the growing challenges of therapy sequencing in DLBCL, FL, and CLL, emphasizing individualized approaches guided by patient characteristics and evolving data.
Amy Goodrich, RN, BSN, MSN, CRNP-AC, reviewed emerging treatments and the growing challenges of therapy sequencing in DLBCL, FL, and CLL, emphasizing individualized approaches guided by patient characteristics and evolving data.
Amy Goodrich, RN, BSN, MSN,...
01/08/2026
Oncology Learning Network APP Institute
Beth Sandy, MSN, CRNP, FAPO
Videos
Navigating Toxicities and Monitoring Strategies for Tyrosine Kinase Inhibitor Therapies for Lung and Breast Cancer
01/05/2026
Beth Sandy, MSN, CRNP, FAPO
Beth Sandy, MSN, CRNP, FAPO, reviewed the clinical use and toxicity management of tyrosine kinase inhibitors across solid tumors at the 2025 Oncology Learning Network APP Institute.
Beth Sandy, MSN, CRNP, FAPO, reviewed the clinical use and toxicity management of tyrosine kinase inhibitors across solid tumors at the 2025 Oncology Learning Network APP Institute.
Beth Sandy, MSN, CRNP, FAPO,...
01/05/2026
Oncology Learning Network APP Institute
Kevin Chen, PharmD, MS, BCOP, CPP
Conference Coverage
Evolving Treatment Landscape of New and Novel Therapies for Solid Tumors
12/17/2025
Kevin Chen, PharmD, MS, BCOP
Kevin Chen, PharmD, discussed the increase in recent biomarker-driven drug approvals for solid tumors at the 2025 JADPRO Annual Conference, highlighting their targeted efficacy, unique toxicity profiles, and the need for clinicians to stay up...
Kevin Chen, PharmD, discussed the increase in recent biomarker-driven drug approvals for solid tumors at the 2025 JADPRO Annual Conference, highlighting their targeted efficacy, unique toxicity profiles, and the need for clinicians to stay up...
Kevin Chen, PharmD, discussed...
12/17/2025
Oncology Learning Network APP Institute
Shila Pandey, DNP, AGPCNP-BC, ACHPN, FPCN
Conference Coverage
Development of an APP-Led Quality Assurance Committee to Enhance Patient Safety and Care Quality
12/11/2025
Shila Pandey, DNP, AGPCNP-BC, ACHPN
At the 2025 JADPRO meeting, Shila Pandey, DNP, shared insights into the development of an advanced-practice-provider-led quality assurance committee designed to improve patient safety and care quality.
At the 2025 JADPRO meeting, Shila Pandey, DNP, shared insights into the development of an advanced-practice-provider-led quality assurance committee designed to improve patient safety and care quality.
At the 2025 JADPRO meeting,...
12/11/2025
Oncology Learning Network APP Institute
Danielle Roman, PharmD, BCOP
Conference Coverage
Evolving Treatments and Strategies for Triple-Positive Metastatic Breast Cancer: Integrating HER2 and Endocrine Therapies
12/11/2025
Danielle Roman, PharmD
Danielle Roman, PharmD, highlighted evolving treatment strategies for hormone receptor–positive, HER2-positive metastatic breast cancer, emphasizing the integration of HER2-targeted therapies, endocrine therapy, and emerging CDK4/6 inhibitors...
Danielle Roman, PharmD, highlighted evolving treatment strategies for hormone receptor–positive, HER2-positive metastatic breast cancer, emphasizing the integration of HER2-targeted therapies, endocrine therapy, and emerging CDK4/6 inhibitors...
Danielle Roman, PharmD,...
12/11/2025
Oncology Learning Network APP Institute

APP Perspectives

Lorinda Coombs
APP Perspectives
Myeloma Care: Patient and Advanced Practice Provider Perspectives
11/17/2023
Lorinda Coombs, PhD, CNS, FNP-BC
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS,...
11/17/2023
Oncology Learning Network APP Institute

Conference Coverage

Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023
Oluwatobi Odetola, MD
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023
Narendranath Epperla, MD, MS
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
Andrew Lin, PharmD
Conference Coverage
Exploring Clinical Approaches to Managing CAR-T and Bispecific Therapy Toxicities
02/17/2026
Andrew Lin, PharmD, reviewed practical strategies for managing cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and cytopenias associated with CAR T-cell and bispecific therapies.
Andrew Lin, PharmD, reviewed practical strategies for managing cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and cytopenias associated with CAR T-cell and bispecific therapies.
Andrew Lin, PharmD, reviewed...
02/17/2026
Oncology Learning Network APP Institute
Donna Catamero, ANP-BC, OCN, CCRC
Conference Coverage
Exploring the Rapidly Evolving Landscape of Targeted Therapy for Multiple Myeloma
02/11/2026
Donna Catamero, ANP-BC, OCN, CCRC
Donna Catamero, ANP-BC, OCN, CCRC, highlighted the rapidly evolving multiple myeloma treatment landscape, with quadruplet therapy now standard in newly diagnosed disease, earlier use of CAR-T therapy in relapse, and emerging bispecific and...
Donna Catamero, ANP-BC, OCN, CCRC, highlighted the rapidly evolving multiple myeloma treatment landscape, with quadruplet therapy now standard in newly diagnosed disease, earlier use of CAR-T therapy in relapse, and emerging bispecific and...
Donna Catamero, ANP-BC, OCN,...
02/11/2026
Oncology Learning Network APP Institute
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP
Conference Coverage
Clinical Strategies for the Assessment and Management of Antibody-Drug Conjugate Toxicities
01/30/2026
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP, reviewed the mechanisms, expanding clinical use, and payload-driven toxicities of antibody-drug conjugates, emphasizing practical strategies for toxicity recognition, management, and optimizing patient...
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP, reviewed the mechanisms, expanding clinical use, and payload-driven toxicities of antibody-drug conjugates, emphasizing practical strategies for toxicity recognition, management, and optimizing patient...
Sri Kota, MSN, BA, APN, AGNP-C,...
01/30/2026
Oncology Learning Network APP Institute
Jessica Walchonski, PA-C, MMS
Conference Coverage
Exploring Key Advances and Emerging Therapies in Gynecologic Oncology
01/23/2026
Jessica Walchonski, PA-C, MMS
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS,...
01/23/2026
Oncology Learning Network APP Institute
Allison Tanner, PA-C
Conference Coverage
Evolving Toxicity Management Strategies for CAR T-Cell and Bispecific Therapies
01/16/2026
Allison Tanner, PA-C
Allison Tanner, PA-C, reviewed the recognition and management of CRS, ICANS, and other evolving toxicities associated with CAR T-cell therapy and bispecific antibodies, emphasizing the need for clinician readiness as cellular therapies...
Allison Tanner, PA-C, reviewed the recognition and management of CRS, ICANS, and other evolving toxicities associated with CAR T-cell therapy and bispecific antibodies, emphasizing the need for clinician readiness as cellular therapies...
Allison Tanner, PA-C, reviewed...
01/16/2026
Oncology Learning Network APP Institute
Amy Goodrich, RN, BSN, MSN, CRNP-AC
Conference Coverage
Refining Treatment Pathways: Data-Driven Approaches to Sequencing in Lymphoma
01/08/2026
Amy Goodrich, RN, BSN, MSN, CPNP-AC
Amy Goodrich, RN, BSN, MSN, CRNP-AC, reviewed emerging treatments and the growing challenges of therapy sequencing in DLBCL, FL, and CLL, emphasizing individualized approaches guided by patient characteristics and evolving data.
Amy Goodrich, RN, BSN, MSN, CRNP-AC, reviewed emerging treatments and the growing challenges of therapy sequencing in DLBCL, FL, and CLL, emphasizing individualized approaches guided by patient characteristics and evolving data.
Amy Goodrich, RN, BSN, MSN,...
01/08/2026
Oncology Learning Network APP Institute
Beth Sandy, MSN, CRNP, FAPO
Videos
Navigating Toxicities and Monitoring Strategies for Tyrosine Kinase Inhibitor Therapies for Lung and Breast Cancer
01/05/2026
Beth Sandy, MSN, CRNP, FAPO
Beth Sandy, MSN, CRNP, FAPO, reviewed the clinical use and toxicity management of tyrosine kinase inhibitors across solid tumors at the 2025 Oncology Learning Network APP Institute.
Beth Sandy, MSN, CRNP, FAPO, reviewed the clinical use and toxicity management of tyrosine kinase inhibitors across solid tumors at the 2025 Oncology Learning Network APP Institute.
Beth Sandy, MSN, CRNP, FAPO,...
01/05/2026
Oncology Learning Network APP Institute
Kevin Chen, PharmD, MS, BCOP, CPP
Conference Coverage
Evolving Treatment Landscape of New and Novel Therapies for Solid Tumors
12/17/2025
Kevin Chen, PharmD, MS, BCOP
Kevin Chen, PharmD, discussed the increase in recent biomarker-driven drug approvals for solid tumors at the 2025 JADPRO Annual Conference, highlighting their targeted efficacy, unique toxicity profiles, and the need for clinicians to stay up...
Kevin Chen, PharmD, discussed the increase in recent biomarker-driven drug approvals for solid tumors at the 2025 JADPRO Annual Conference, highlighting their targeted efficacy, unique toxicity profiles, and the need for clinicians to stay up...
Kevin Chen, PharmD, discussed...
12/17/2025
Oncology Learning Network APP Institute
Shila Pandey, DNP, AGPCNP-BC, ACHPN, FPCN
Conference Coverage
Development of an APP-Led Quality Assurance Committee to Enhance Patient Safety and Care Quality
12/11/2025
Shila Pandey, DNP, AGPCNP-BC, ACHPN
At the 2025 JADPRO meeting, Shila Pandey, DNP, shared insights into the development of an advanced-practice-provider-led quality assurance committee designed to improve patient safety and care quality.
At the 2025 JADPRO meeting, Shila Pandey, DNP, shared insights into the development of an advanced-practice-provider-led quality assurance committee designed to improve patient safety and care quality.
At the 2025 JADPRO meeting,...
12/11/2025
Oncology Learning Network APP Institute
Danielle Roman, PharmD, BCOP
Conference Coverage
Evolving Treatments and Strategies for Triple-Positive Metastatic Breast Cancer: Integrating HER2 and Endocrine Therapies
12/11/2025
Danielle Roman, PharmD
Danielle Roman, PharmD, highlighted evolving treatment strategies for hormone receptor–positive, HER2-positive metastatic breast cancer, emphasizing the integration of HER2-targeted therapies, endocrine therapy, and emerging CDK4/6 inhibitors...
Danielle Roman, PharmD, highlighted evolving treatment strategies for hormone receptor–positive, HER2-positive metastatic breast cancer, emphasizing the integration of HER2-targeted therapies, endocrine therapy, and emerging CDK4/6 inhibitors...
Danielle Roman, PharmD,...
12/11/2025
Oncology Learning Network APP Institute
APP Institute Oncology

The Advanced Practice Provider (APP) Institute is a new offering from the Oncology Learning Network that provides microburst education to oncology advanced practitioners. The platform offers year-round digital non-accredited learning modules through animated short videos, multimedia interviews with key opinion leaders, interactive content to test your knowledge, and more!

 

December 18-19, 2025 | Register Now

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use